Category: HIV

Civil Society Speaks: Fighting for Universal Access To Dolutegravir (DTG)!

Source : The Global Network of People living with HIV GNP+ What do people living with HIV need to know about Dolutegravir? What do our communities need to know about viral resistance to first line ARVs? GNP+ invites you to...

/ 16 February 2018

Global Fund MENA Regional Platform is relaunched

ITPC-MENA continues as the host for the Middle East and North Africa region As a key component of the Global Fund’s Community, Rights and Gender Strategic Initiative, the Regional Platform for Communication and Coordination will continue to support and facilitate...

/ 8 February 2018

ITPC-MENA organize its Middle East and North Africa Community Advisory board (MENACAB)

The International Treatment Preparedness Coalition in Middle East and North Africa (ITPC-MENA) is organizing its Middle East and North Africa Community Advisory board (MENACAB), in late November in Marrakech.The MENACAB is a treatment advocate network which main aim is to improve...

/ 15 October 2017

ITPC-MENA at the Mediterranean Symposium on HIV and Hepatitis (AFRAMED 2017)

ITPC-MENA at 2nd Mediterranean Symposium on HIV and Hepatitis (AFRAMED 2017) Join ITPC-MENA at AFRAMED 2017 – Hammamet Join ITPC_MENA at 2nd Mediterranean Symposium on HIV and Hepatitis (AFRAMED 2017) in Tunis and Hammamet from 27 – 30 September 2017. We...

/ 21 September 2017

2nd Francophone Symposium AFRAMED on HIV and Hepatitis

2nd Francophone Symposium AFRAMED on HIV and Hepatitis September 28 to 30, Hammamet, Tunisie Following the success of the first experience in Algeria, the second edition of AFRAMED symposium will be hosted by Tunisia. This AFRAMED edition is in line...

/ 14 September 2017

A new victory for ITPC-MENA : Bristol-Myers Squibb extends its voluntary license on Atazanavir to Egypt

The 9th International AIDS Society Conference on HIV / AIDS 2017 : Bristol-Myers Squibb extends its voluntary license on Atazanavir to Egypt, a victory for ITPC-MENA Today, at the World Conference on AIDS, which is currently taking place in Paris...

/ 25 July 2017

BLOG: We want dolutegravir for all, and we want it now

Source: makemedicinesaffordable Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published on the Huffington Post here. We’re calling for a compulsory license on a ‘new’ HIV drug to be...

/ 25 July 2017

HIV Activists Denounce ViiV for Denying 3.5 million People Access to Optimal Treatment

Source : ITPC GLOBAL Today, Monday, 24 July 2017, during the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), HIV treatment activists from around the world collectively blocked access to ViiV Healthcare’s promotional booth and stormed its...

/ 24 July 2017

ITPC MENA IN THE REGIONAL CONSULTATION ON ACCELERATING ACCESS TO THE CONTIUUM OF HIV CARE: FOCUS ON HIV TESTING

Beirut, Lebanon, 12–14 July 2017 By the end of 2015, the estimated number of people living with HIV in the Region had reached 330 000. With a continuously growing epidemic coupled with low coverage of ART, standing at 14% of...

/ 21 July 2017

New WHO Guidance Report- Treatment Failure and Drug Resistance

WHO urges action against HIV drug resistance threat 20 JULY 2017 | GENEVA - WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted in several countries. The Organization warns...

/ 20 July 2017